Navigation Links
Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
Date:12/10/2007

marrow to produce platelets.(6,7)

"These long-term results on safety and efficacy are encouraging and suggest that PROMACTA, once approved, may provide physicians with a new treatment option to raise and maintain patients' platelet levels and alleviate their ITP symptoms," said James B. Bussel, MD, director of the Platelet Disorders Center, Children's Blood Foundation Division at New York-Presbyterian Hospital/Weill Cornell Medical Center, and principal investigator for this trial.

The EXTEND study

EXTEND is a study designed to assess the long-term safety and efficacy of PROMACTA as an oral treatment for increasing platelets in patients with chronic ITP. EXTEND is an open-label study for patients who had participated in previous PROMACTA trials and were eligible to receive PROMACTA.(8)

Study design(8)

Chronic ITP patients were administered a starting dose of 50 mg/day (which can be increased to 75 mg/day at any time after 3 weeks) in order to reach a platelet count of greater than or equal to 50,000/microliters or greater than or equal to 100,000/microliters if patients were receiving concomitant ITP medication (stage 1). Then, concomitant ITP medications, if taken at study entry, were tapered to a minimal dose or discontinued entirely (stage 2), whilst maintaining a platelet count of greater than or equal to 50,000/microliters. PROMACTA was then titrated to a minimal effective dose (25-75 mg/day) required to maintain platelet counts of 50,000/microliters-200,000/microliters (stage 3). PROMACTA is continued for as long as patients continue to benefit and platelets remain greater than or equal to 50,000/microliters (stage 4). Bleeding incidences and severity were assessed using the WHO bleeding scale (Grade 0-4).

Study results(1)

At the time of this analysis PROMACTA had been administered to 94 patients. Evaluable subjects (n=89) had a median treatment duration of 151 days, with the longest treatment duration a
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...LYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-USNewswi...ticle that questions why currently available medic...are being ignored, ECRI Institute, an independent ...he evidence on Finasteride for Prevention of Pros...er 13, 2009, New York Times article, " Drugs to ...
(Date:11/20/2009)...IS, Tenn., Nov. 20 Smi...ion is pleased to announce the signing of a techno...epartment of Defense that may lead to the creation...ionize the treatment of the limbs of soldiers who ... Defense Advanced Research Projects Agency (DARPA)...
(Date:11/19/2009)...EE, Ireland, Nov. 19 Warner Chilco...g of its previously announced secondary offering o...the public of $22.25 per share. The selling share... Partners, DLJ Merchant Banking, J.P. Morgan Partn...rtners, L.P., certain other institutional investor...
Breaking Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4BibsToGo com Answers 3A How Can a Traditional Baby Product Help Corporate America Look Better 3F 60682 1BibsToGo com Answers 3A How Can a Traditional Baby Product Help Corporate America Look Better 3F 60682 2Health Integrated Announces Turnkey Model of Care Program for Special Needs Health Plans 60677 1Health Integrated Announces Turnkey Model of Care Program for Special Needs Health Plans 60677 2Health Integrated Announces Turnkey Model of Care Program for Special Needs Health Plans 60677 3Health Robotics Announces December Launch of the i v SOFT 28TM 29 Workflow Engine at ASHP in Las Vegas 14719 1Health Robotics Announces December Launch of the i v SOFT 28TM 29 Workflow Engine at ASHP in Las Vegas 14719 2Health Robotics Announces December Launch of the i v SOFT 28TM 29 Workflow Engine at ASHP in Las Vegas 14719 3
... Pharmaceutical,Research & Development, L.L.C. (J&...Administration (FDA) requires additional informati...pplication (NDA) for DORIBAX(TM),(doripenem for in...eumonia,also known as nosocomial pneumonia (NP), i...In response to the J&JPRD application seeking appr...
...rumo Heart, Inc. today,announced the discharge of ...t(TM) Left Ventricular Assist System (LVAS). The p...e University of Michigan Health,System, 15 days af...ar-old man from Livonia, Michigan, who has been,su... is the first U.S.,patient to receive a ventricula...
Other Medicine Technology:FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 2FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 3FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 4FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 5Discharge of First U.S. DuraHeart(TM) Patient 2
(Date:11/20/2009)...PRNewswire-FirstCall/ -- Cardio Vascular,Medical D... , a leading,developer of advanced cardiovascular ...ny,s Board of Directors has decided to initiate pa...st for its proprietary next-generation,"steerable ...rocedures. , Cardio Vascular Medical Devi...
(Date:11/20/2009)... the Journal of the National Cancer Institute di... appear in news coverage of cancer research. The e...journals to help alleviate the problem. , Lisa M... M.S., of Center for Medicine and the Media at the...l Practice in New Hampshire, and Barnett S. Kramer...
(Date:11/20/2009)... TX, the new addition to blue sky scrubs will ensu...USA. , Austin, TX (PRWEB)...ndent medical scrubs brand which focuses primarily...on of hospital uniforms and surgical scrub hats. ...line boutique, the Austin, TX business has grown t...
(Date:11/20/2009)... to continue, CDC says, , , FRIDAY, Nov...States are seeing declines in H1N1 swine flu activ...ile the disease remains widespread in 43 states, t..., "We are beginning to see some declines in inf...till a lot of influenza everywhere," Dr. Anne Schu...
(Date:11/20/2009)...PRNewswire-FirstCall/ -- Omnicell, Inc. (Nasdaq: ...cute healthcare facilities, announced today the co...ay Healthcare Conference at the New York Palace H...andall A. Lipps, founder, chairman, president &... Date: Tuesday, December 1, 2009 ,, Time: 1...
Breaking Medicine News(10 mins):Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:Blue Sky Scrubs Secures a Second Texas Manufacturer 2Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:Omnicell to Present at Piper Jaffray Healthcare Conference 2
...n an effort to better define and ultimately addres...om The University of Texas M. D. Anderson Cancer C...f strength or energy, major effects of fatigue and... Nursing Society (ONS), Loretta A. Williams, Ph.D....
...15 AMIA will host its,2008 Spring Congress May 29.... The meeting brings together experts and professi...cademic and non-profit sector across the,spectrum ...acks: Clinical research informatics (CRI), Electro...
...ients self-medicate with over-the-counter remedies... -, BETHESDA, Md., May 15 Despite daily use of,d... control,gastroesophageal reflux disease (GERD) sy...n and heartburn. These,breakthrough symptoms lead ...
... AGA Medical Corporation ("AGA"),announced today ...ER(R),Vascular Plug III ("AVP III"). AGA also anno... device in the European Union. The AVP III,further...., "We believe the new AVP III is another strong ...
...sk than Hispanics, but genetics determines who get...s) -- Genetic differences may explain why white me... men, information which may help doctors identify ...h Texas and looked for mutations from the nuclear ...
...harmaceutical research and,development (R&D) is a ...d,a billion dollars of investment to turn a molecu... the journey from discovery to market, is filled,w...ovie created by Johnson & Johnson Pharmaceutical R...
Other Medicine News:Health News:Study takes a step toward better defining fatigue 2Health News:Study takes a step toward better defining fatigue 3Health News:The 2008 AMIA Spring Congress to Showcase Best Practices and Innovations in Biomedical and Health Informatics Research and Education 2Health News:The 2008 AMIA Spring Congress to Showcase Best Practices and Innovations in Biomedical and Health Informatics Research and Education 3Health News:Nearly 40 Percent of GERD Patients Taking PPIs Experience Recurring Symptoms 2Health News:Nearly 40 Percent of GERD Patients Taking PPIs Experience Recurring Symptoms 3Health News:Nearly 40 Percent of GERD Patients Taking PPIs Experience Recurring Symptoms 4Health News:AGA Medical Corporation Receives CE Mark Approval for the AMPLATZER(R) Vascular Plug III 2Health News:Genes Play Part in Prostate Cancer Among Races 2
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: